{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:57:05Z","timestamp":1785859025333,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Diabetes Endocrinol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Type 1 diabetes mellitus (T1D) is an autoimmune disease caused by destruction of pancreatic islet beta-cells. There is significant residual beta-cell function, measured through circulating C-peptide, present at the time of T1D diagnosis but this subsequently decreases with time. Higher residual beta-cell function at diagnosis associates with better glycaemic control and less glucose variability, and later in the disease course with less hypoglycaemia, lower glucose variability and fewer microvascular complications. There is therefore value in preserving residual beta cell function in new onset T1D Immunotherapeutic agents can protect residual beta-cell function in type 1 diabetes. However, clinical trials of such agents, whilst demonstrating C-peptide preservation in short term studies, have yet to be taken forward into routine clinical care due to concerns around safety and long-term efficacy. Here we report the case of a gentleman with newly diagnosed T1D whose glycaemic control and insulin requirement improved whilst on a five year infusion programme of infliximab, a monoclonal antibody against TNF-alpha, for colitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 52-year-old White Caucasian man was diagnosed with T1D in August 2018. Glucose was 25.6 mmol\/L, HbA1c was 98mmol\/mol and GAD antibodies were strongly positive. HbA1c marginally improved to 91mmol\/mol following initiation of insulin detemir 5 units at night and 1:10\u00a0g of insulin aspart (November 2018). In June 2019, he developed rectal bleeding and abdominal pain. Following colonoscopy, he was diagnosed with \u201cindeterminate colitis\u201d and commenced on 6-weekly infusions of 400-450\u00a0mg infliximab. Thus far, he has received 32 doses and achieved colitis remission. Following infliximab initiation there was increased frequency of mild-moderate hypoglycaemia and he was gradually weaned off and discontinued detemir in June 2020. Since then, HbA1c improved from 57mmol\/mol in August 2019 to 52mmol\/mol in April 2022, remaining stable at 51mmol\/mol. His most recent HbA1c is 54mmol\/mol in February 2024. His c-peptide was 550pmol\/L in October 2022 and 442pmol\/L in February 2024, suggesting well-preserved beta-cell function almost 6 years post-diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our patient\u2019s improvement in glycaemic control can be explained by immunomodulation and C peptide preservation from infliximab. With the growing focus on type 1 diabetes disease modulation and working towards an \u2018insulin free T1D\u2019, our findings strengthen the evidence base for the repurposing of and long-term treatment with anti-TNF-\u03b1 agents to preserve beta-cell function in new onset T1D.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40842-024-00185-6","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:02:22Z","timestamp":1725926542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term TNF-alpha therapy for preserving beta cell function in new onset type 1 diabetes: a case report"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-5180","authenticated-orcid":false,"given":"Adya","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"issue":"11","key":"185_CR1","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.2337\/dci21-0043","volume":"44","author":"RIG Holt","year":"2021","unstructured":"Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, et al. The management of type 1 diabetes in adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44(11):2589\u2013625.","journal-title":"Diabetes Care"},{"issue":"4","key":"185_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/dmrr.943","volume":"25","author":"JP Palmer","year":"2009","unstructured":"Palmer JP. C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev. 2009;25(4):325\u20138.","journal-title":"Diabetes Metab Res Rev"},{"issue":"10205","key":"185_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S0140-6736(19)32127-0","volume":"394","author":"CM Dayan","year":"2019","unstructured":"Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet. 2019;394(10205):1286\u201396.","journal-title":"Lancet"},{"issue":"7","key":"185_CR4","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.2337\/dc18-0465","volume":"41","author":"BM Shields","year":"2018","unstructured":"Shields BM, McDonald TJ, Oram R, Hill A, Hudson M, Leete P, et al. C-Peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase. Diabetes Care. 2018;41(7):1486\u201392.","journal-title":"Diabetes Care"},{"issue":"2","key":"185_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/pedi.12135","volume":"15","author":"DE VanBuecken","year":"2014","unstructured":"VanBuecken DE, Greenbaum CJ. Residual C-peptide in type 1 diabetes: what do we really know? Pediatr Diabetes. 2014;15(2):84\u201390.","journal-title":"Pediatr Diabetes"},{"issue":"10","key":"185_CR6","doi-asserted-by":"publisher","first-page":"bvab127","DOI":"10.1210\/jendso\/bvab127","volume":"5","author":"ALJ Carr","year":"2021","unstructured":"Carr ALJ, Oram RA, Marren SM, McDonald TJ, Narendran P, Andrews RC. Measurement of peak C-Peptide at diagnosis informs Glycemic Control but not hypoglycemia in adults with type 1 diabetes. J Endocr Soc. 2021;5(10):bvab127.","journal-title":"J Endocr Soc"},{"issue":"1","key":"185_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/bmb\/ldab027","volume":"140","author":"LA Allen","year":"2021","unstructured":"Allen LA, Dayan CM. Immunotherapy for type 1 diabetes. Br Med Bull. 2021;140(1):76\u201390.","journal-title":"Br Med Bull"},{"issue":"3","key":"185_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.180.3.995","volume":"180","author":"XD Yang","year":"1994","unstructured":"Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med. 1994;180(3):995\u20131004.","journal-title":"J Exp Med"},{"issue":"7","key":"185_CR9","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2337\/dc09-0054","volume":"32","author":"L Mastrandrea","year":"2009","unstructured":"Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, et al. Etanercept Treatment in Children with New-Onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care. 2009;32(7):1244\u20139.","journal-title":"Diabetes Care"},{"key":"185_CR10","unstructured":"Pan A, Gerriets V. Etanercept. StatPearls. Treasure Island (FL)2024."},{"issue":"21","key":"185_CR11","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","volume":"383","author":"T Quattrin","year":"2020","unstructured":"Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, Xia Y, et al. Golimumab and Beta-cell function in Youth with New-Onset type 1 diabetes. N Engl J Med. 2020;383(21):2007\u201317.","journal-title":"N Engl J Med"},{"key":"185_CR12","unstructured":"Fatima R, Bittar K, Aziz M, Infliximab. StatPearls. Treasure Island (FL)2024."},{"key":"185_CR13","doi-asserted-by":"crossref","unstructured":"Rollan MPC, Schwartz R. R A. Current knowledge of immunosuppression as a risk factor for skin cancer development. Crit Reviews Oncol Hematol. 2022;177(September 2022).","DOI":"10.1016\/j.critrevonc.2022.103754"},{"issue":"7","key":"185_CR14","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.2337\/dc13-0199","volume":"36","author":"K Timper","year":"2013","unstructured":"Timper K, Hruz P, Beglinger C, Donath MY. Infliximab in the treatment of Crohn disease and type 1 diabetes. Diabetes Care. 2013;36(7):e90\u20131.","journal-title":"Diabetes Care"},{"issue":"9","key":"185_CR15","doi-asserted-by":"publisher","first-page":"e031586","DOI":"10.1136\/bmjopen-2019-031586","volume":"9","author":"A Lynam","year":"2019","unstructured":"Lynam A, McDonald T, Hill A, Dennis J, Oram R, Pearson E, et al. Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18\u201350 years. BMJ Open. 2019;9(9):e031586.","journal-title":"BMJ Open"},{"issue":"1","key":"185_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","volume":"37","author":"DM Nathan","year":"2014","unstructured":"Nathan DM, Group DER. The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9\u201316.","journal-title":"Diabetes Care"},{"issue":"5","key":"185_CR17","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1172\/JCI117936","volume":"95","author":"GS Hotamisligil","year":"1995","unstructured":"Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Investig. 1995;95(5):2409\u201315.","journal-title":"J Clin Investig"},{"key":"185_CR18","doi-asserted-by":"crossref","unstructured":"Rapini N, Schiaffini R, Fierabracci A. Immunotherapy strategies for the Prevention and treatment of distinct stages of type 1 diabetes: an overview. Int J Mol Sci. 2020;21(6).","DOI":"10.3390\/ijms21062103"},{"key":"185_CR19","doi-asserted-by":"publisher","first-page":"o2798","DOI":"10.1136\/bmj.o2798","volume":"379","author":"G Iacobucci","year":"2022","unstructured":"Iacobucci G. Type 1 diabetes: US approves drug that can delay onset. BMJ. 2022;379:o2798.","journal-title":"BMJ"},{"key":"185_CR20","unstructured":"NICE. Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition 2022. https:\/\/www.nice.org.uk\/guidance\/awaiting-development\/gid-ta10981. Accessed 22 February 2024."}],"updated-by":[{"DOI":"10.1186\/s40842-025-00217-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000}}],"container-title":["Clinical Diabetes and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-024-00185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-024-00185-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-024-00185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:56:51Z","timestamp":1740117411000},"score":1,"resource":{"primary":{"URL":"https:\/\/clindiabetesendo.biomedcentral.com\/articles\/10.1186\/s40842-024-00185-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1186\/s40842-024-00185-6","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40842-025-00217-9","asserted-by":"object"}]},"ISSN":["2055-8260"],"issn-type":[{"value":"2055-8260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Following publication of the original article [1], the statements under Ethics approval and consent to participate and Consent for publication sections are need to swap around.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40842-025-00217-9","URL":"https:\/\/doi.org\/10.1186\/s40842-025-00217-9","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient whose case we report, in accordance with the declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}